By Leigh Kamping-Carder ( August 6, 2009, 5:39 PM EDT) -- Elan Corp. PLC went on the offensive Thursday against Biogen Idec Inc., its partner in developing the multiple sclerosis treatment Tysabri, to secure a court order that a $1 billion acquisition deal with a Johnson & Johnson affiliate does not violate its collaboration agreement with Biogen Idec....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.